Fracture risk in Danish men with prostate cancer: A nationwide register study

BJU International

Volumn 100, Issue 4, 2007, Pages 749-754

  Abrahamsen, Bo ^a   Nielsen, Morten F ^b   Eskildsen, Peter ^c   Andersen, Jens Thorup ^c   Walter, Steen ^b   Brixen, Kim ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c RASK Koege ^*  (Denmark)

Author keywords

Androgen deprivation therapy; Epidemiology; Hip fracture; Male osteoporosis; Prostate cancer

Indexed keywords

ANDROGEN; ANTIANDROGEN; GONADORELIN AGONIST;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; REGISTER; RISK FACTOR; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; CASE-CONTROL STUDIES; DENMARK; FRACTURES, BONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; OSTEOPOROSIS; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 34548456518     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07163.x     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66
2. Brasso K, Ingimarsdottir IJ, Thomassen L, Friis S, Iversen P. [Prostate cancer in Denmark 1943-2002]. Ugeskr Laeger 2007 169 : 129 32
3. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000 88 (Suppl. 2989 94
4. Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005 61 : 1285 90
5. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002 360 : 103 6
6. Studer UE, Whelan P, Albrecht W et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006 24 : 1868 76
7. Denham JW, Steigler A, Lamb DS et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005 6 : 841 50
8. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999 161 : 1219 22
9. Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001 345 : 948 55
10. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004 89 : 3841 6
11. Lee H, McGovern K, Finkelstein JS, Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 2005 104 : 1633 7
12. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005 352 : 154 64
13. Melton LJ III., Alothman KI, Khosla S, Achenbach SJ, Oberg AL, Zincke H. Fracture risk following bilateral orchiectomy. J Urol 2003 169 : 1747 50
14. Dickman PW, Adolfsson J, Astrom K, Steineck G. Hip fractures in men with prostate cancer treated with orchiectomy. J Urol 2004 172 : 2208 12
15. Heller RF, Dobson AJ, Attia J, Page J. Impact numbers: measures of risk factor impact on the whole population from case-control and cohort studies. J Epidemiol Community Health 2002 56 : 606 10
16. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004 45 : 1330 7
17. Kanis JA, Johnell O, Oden A et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int 2004 15 : 20 6
18. Pongchaiyakul C, Nguyen ND, Jones G, Center JR, Eisman JA, Nguyen TV. Asymptomatic vertebral deformity as a major risk factor for subsequent fractures and mortality: a long-term prospective study. J Bone Miner Res 2005 20 : 1349 55
19. Ryg J, Gram J, Overgaard S, Brixen K. Vertebral fractures are highly prevalent in hip fracture patients: results from a 1 year consecutive cohort. J Bone Mineral Res 2006 Suppl. 1 : S55, Abstract
20. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006 175 : 136 9
21. Lopez AM, Pena MA, Hernandez R, Val F, Martin B, Riancho JA. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 2005 16 : 707 11
22. Townsend MF, Sanders WH, Northway RO, Graham SD Jr. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997 79 : 545 50
23. Diamond TH, Winters J, Smith A et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001 92 : 1444 50
24. Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006 176 : 972 8
25. Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer 2006 107 : 530 5
26. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004 96 : 879 82
27. Dearnaley DP, Sydes MR, Mason MD et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003 95 : 1300 11
28. Eriksson S, Eriksson A, Stege R, Carlstrom K. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 1995 57 : 97 9
29. Steiner MS, Pound CR. Phase IIA clinical trial to test the efficacy and safety of toremifene in men with high-grade prostatic intraepithelial neoplasia. Clin Prostate Cancer 2003 2 : 24 31
30. Lara PN Stadler WM, Longmate J et al. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res 2006 12 : 1556 63